# Vaccines Published articles for Vaccines. This is one page of public article previews, not the complete archive. Follow Next page to continue. Summaries are not the original full articles. ## Startup Claims To Use AI-Created Viruses To Treat a Patient DevFeed: [Startup Claims To Use AI-Created Viruses To Treat a Patient]() Original publisher: [Read original article]() Author: BeauHD Published: 2026-10-22T03:30:00Z Content type: news Language: en Sources: [Slashdot]() Topics: [Artificial Intelligence]() Tags: [ai](), [antibiotics](), [artificial-intelligence](), [biology](), [biotech](), [cancer](), [dna](), [doctors](), [infection](), [proteins](), [startup](), [the-new-york-times](), [vaccines](), [viruses]() ### AI overview Scientists say they administered an AI-designed phage to a patient with an antibiotic- and phage-resistant E. coli infection. Radical Numerics says it used Omnii to design T7 phages with altered legs intended to bind the resistant bacteria; lab-produced phages reportedly infected and killed microbes, and the FDA authorized a trial after safety testing. Earlier work with Evo 2 generated 700,000 candidate genomes, of which 16 of 285 synthesized genomes produced viable viruses. The patient's details and doctors were not disclosed, and the report says the research had not been peer-reviewed and the treatment's success was uncertain. The company says its goal is to tailor phages in days. ### Source excerpt An anonymous reader quotes a report from The New York Times: For the first time, scientists say they have used viruses designed by artificial intelligence to treat a human patient. Researchers announced on Tuesday that they had administered the virus, known as a phage, to a patient suffering from a deadly bacterial infection. Phages attack bacteria, and the hope is that this one will kill the microbes causing the infection. Radical Numerics, the start-up that created the viruses, posted a technical report about them on its website. But the company declined to provide information about the patient or the doctors running the trial, citing confidentiality requirements. [...] In 2025, researchers at the Arc Institute in Palo Alto, Calif., created an A.I. model called Evo 2, which they trained on millions of DNA sequences, including phage genes. They prompted Evo 2 to make new genomes similar to those in a group of phage species. The A.I. generated 700,000 virus genomes. The team synthesized DNA molecules from 285 genomes and inserted them into bacteria. The researchers found that 16 of the genomes gave rise to viable viruses. Three members of the Evo team, including Dr. Nguyen, left to found Radical Numerics. In June, the company unveiled a new A.I. model, called Omnii, based on some of the same principles as Evo. Omnii can be trained not just on DNA but also on other aspects of biology, such as the structures of proteins and molecules that keep genes turned on or off. The company is now using Omnii to tackle a range of challenges, including designing cancer vaccines and recognizing the risk that a virus may cause a pandemic. Among these efforts is the first trial of A.I.-designed phage therapy. The researchers created variations of a phage called T7. The virus, which only infects E. coli, looks like a microscopic Apollo lunar lander: a ball-shaped protein shell that holds its DNA atop six leglike protrusions. To infect a bacterium, T7 lands on its surface, using its le